

(19) **DANMARK**

(10) **DK/EP 3021832 T3**



(12) **Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 9/08 (2006.01)** **A 61 K 47/40 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2021-05-25**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2021-02-24**
- (86) Europæisk ansøgning nr.: **14739817.6**
- (86) Europæisk indleveringsdag: **2014-07-16**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-05-25**
- (86) International ansøgning nr.: **EP2014065204**
- (87) Internationalt publikationsnr.: **WO2015007760**
- (30) Prioritet: **2013-07-19 EP 13177268**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Boehringer Ingelheim Vetmedica GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Tyskland**
- (72) Opfinder: **AVEN, Michael, Boehringer Ingelheim GmbH, Corporate Patents, Bingerstrasse 173, 55216 Ingelheim Am Rhein, Tyskland**  
**LUKAS, Tim, Boehringer Ingelheim GmbH, Corporate Patents, Bingerstrasse 173, 55216 Ingelheim Am Rhein, Tyskland**
- (74) Fuldmægtig i Danmark: **AWA Denmark A/S, Strandgade 56, 1401 København K, Danmark**
- (54) Benævnelse: **KONSERVEREDE ETHERIFICERED E CYCLODEXTRINDERIVATER INDEHOLDENDE FLYDENDE VANDIG FARMACEUTISK SAMMENSÆTNING**
- (56) Fremdragne publikationer:  
**EP-A1- 1 920 785**  
**WO-A1-2004/089418**  
**US-A1- 2004 152 664**  
**BREWSTER ET AL: "Cyclodextrins as pharmaceutical solubilizers", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 59, no. 7, 24 August 2007 (2007-08-24), pages 645-666, XP022211985, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2007.05.012**  
**BASSANI V L ET AL: "ENHANCED WATER-SOLUBILITY OF ALBENDAZOLE BY HYDROXYPROPYL-ss-CYCLODEXTRIN COMPLEXATION", JOURNAL OF INCLUSION PHENOMENA AND MOLECULAR RECOGNITION IN CHEMISTRY, KLUWER, DORDRECHT, NL, vol. 25, no. 1-3, 1 March 1996 (1996-03-01), pages 149-152, XP008076331, ISSN: 0923-0750, DOI: 10.1007/BF01041557**  
**PIEL G ET AL: "DEVELOPMENT OF A PARENTERAL AND AN ORAL FORMULATION OF ALBENDAZOLE WITH CYCLODEXTRINS", SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA PRATIQUES, PARIS, FR, vol. 9, no. 3, 1 January 1999 (1999-01-01), pages 257-260, XP008076739, ISSN: 1157-1497**



# DESCRIPTION

## FIELD OF THE INVENTION

**[0001]** The invention relates to the field of medicine, particularly veterinary medicine. In particular, the invention relates to a novel preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives, one or more water-soluble preservatives and at least one pharmaceutically active compound as claimed.

## BACKGROUND OF THE INVENTION

**[0002]** Cyclodextrins are cyclic oligosaccharides containing six, seven, or eight ( $\alpha$ -1,4)-linked D-glucopyranoside units resulting in alpha( $\alpha$ )-, beta( $\beta$ )- and gamma( $\gamma$ )-cyclodextrins. In general, cyclodextrins are pharmaceutical excipients that can solubilise various poorly soluble drugs/molecules through the formation of water-soluble drug-cyclodextrin complexes (Loftsson T et al., Journal of Pharmaceutical Sciences 2012, 101(9):3019-3032). More specifically, cyclodextrins in aqueous solution form inclusion complexes with water-insoluble or poorly soluble drugs by taking up the lipophilic moiety of the drug molecule into the cavity of the cyclodextrin, which is hydrophobic (Brewster ME et al., Advanced Drug Delivery Reviews 2007, 59: 645-666). However, non-inclusion drug-cyclodextrin complexes can also be formed. The higher the cyclodextrin concentration increases, the higher the formation of aggregates of cyclodextrin molecules and self-assembled complexes. A further aspect with cyclodextrin containing pharmaceutical compositions is the formation of self-assembled complexes and/or formation of aggregates (Messner M et al., International Journal of Pharmaceutics 2011, 408: 235-247). Excipients that solubilize and stabilize such aggregates include small ionized molecules such as salts of organic acids and bases.

**[0003]** A substantial problem with pharmaceutical compositions including cyclodextrins is to produce pharmaceutical compositions which are preserved against microbial growth. Such preserved compositions are particularly important for storage of containers containing multiple-dose compositions. Typical preservatives are relatively ineffective at normal concentrations in such compositions, as compositions including such preservatives are unable to meet or pass standard preservative efficacy tests (for example USP <51> or Pharm. Eur. 5.1.3. It is believed that the preservative forms a complex with cyclodextrin and consequently is rendered ineffective or has reduced effectiveness as a preservative. Thus, the preservative loses its full activity by complex formation. The formation of these complexes between preservative and cyclodextrin further reduce the solubility of the active drug substance (Loftsson T et al., Drug Development and Industrial Pharmacy 1992, 18(13): 1477-1484).

**[0004]** Certain etherified  $\beta$ -cyclodextrin derivatives are known to improve solubility of sparingly soluble drugs, see WO 85/02767. However, in WO 85/02767 only the use of etherified  $\beta$ -



cyclodextrin derivatives up to a concentration of 10 % is described. A molar ratio of drug to etherified  $\beta$ -cyclodextrin derivative of 1:6 to 4:1 was contemplated. The solubility of flubendazol within the above given ratio was only increased by a factor 30. However, those formulations are not suitable for the preparation of pharmaceutical compositions comprising substituted benzimidazole derivatives, such as pimobendan.

**[0005]** Further prior art is as follows:

US 2004/152664 is directed to compositions comprising cyclodextrin derivatives and prednisolone.

**[0006]** WO 2004/089418 deals with a fluoroquinolone comprising aqueous formulations of a pH between 4 and 7.

**[0007]** EP 1 920 785 discloses a liquid preparation comprising a complex of pimobendan and cyclodextrin. Brewster ME et al. (Advanced Drug Delivery Reviews 2007, 59(7): 645-666) describe cyclodextrins as pharmaceutical solubilizers.

**[0008]** Bassani VL et al. (Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, 1996, 25(1 - 3): 149-152) refer to the enhanced water-solubility of albendazole by hydroxypropyl- $\beta$ -cyclodextrin complexation.

**[0009]** The article of Piel G and co-workers (Sciences Techniques et Pratiques STP Pharma Pratiques 1999, 9(3): 257-260) is directed to the development of a parenteral and an oral formulation of albendazole with cyclodextrins.

**[0010]** This enables the development of a pharmaceutical composition for parenteral use but due to the reduced shelf-life of unpreserved compositions, it does not enable the development of a pharmaceutical multiple-dose composition for oral use. Due to the risk of severe tolerance problems and also due to concerns by pet-owners that inflammation in the subcutis following injections is considered to be a risk factor in the development of sarcomas, it is highly desirable to develop an oral pharmaceutical composition.

**[0011]** Due to some animals' intense sense of taste, it is particularly difficult to formulate a medication that can be administered orally and which the animal accepts resulting in an easy to use medication for animals, in particular companion animals, such as dogs, cats and horses (sufficiently good palatability).

**[0012]** The objective underlying the present invention is therefore to provide a pharmaceutical composition which overcomes the problems of the prior art as described above. Particularly, a pharmaceutical composition containing a sparingly water-soluble pharmaceutical active compound at palatable pH values (e.g.  $\geq$  pH 3) shall be provided to be administered in adequate form to a subject in need thereof.

## **SUMMARY OF THE INVENTION**

**[0013]** It is therefore provided a preserved liquid aqueous pharmaceutical composition as claimed comprising

- one or more etherified cyclodextrin derivatives as claimed;
- one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof; and
- at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;

wherein preferably the solubility of the at least one pharmaceutically active compound in water in the range of 15 to 25°C is defined as follows:

the at least one pharmaceutically active compound is poorly water-soluble if more than 100 mL of water per gram compound have to be used; it is very poorly water-soluble if more than 1000 mL of water per gram compound have to be used; and it is water-insoluble if more than 10,000 mL water per gram compound have to be used to solubilise the compound; and

with the proviso that corticosteroids, in particular prednisolone and its prodrug prednisolone acetate (see US 2004/152664), and fluoroquinolones, in particular ciprofloxacin, gatifloxacin, moxifloxacin, sitafloxacin, lomefloxacin, grepafloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin, trovafloxacin and the like (see WO 2004/089418), are independently from each other excluded as pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;

and wherein the pH of the composition is between 2.5 to 5.

**[0014]** The present invention is also directed to the liquid pharmaceutical composition as claimed for use in a method for treating a subject in need of such treatment, preferably an animal, in particular a companion animal, even more preferred horse, dog or cat, guinea pig, hamster, cattle, goat, sheep, in particular cat or dog, selected from among the indications: heart diseases, particularly a hypertrophic cardiomyopathy, more particularly heart failure (HF), congestive heart failure (CHF), acute CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), and heart failure due to HCM, RCM, DCM and/or UCM.

**[0015]** It is also disclosed a process for producing the pharmaceutical composition as claimed comprising the steps

- adding at least one pharmaceutically active compound, one or more etherified cyclodextrin derivatives, one or more water-soluble preservatives, optionally one or more antioxidants and optionally at least one water-soluble polymer to water and mixing under stirring,
- adjusting the pH value using a pH adjustment agent,




wherein preferably the one or more water-soluble preservatives are added after the addition of the at least one pharmaceutically active compound.

**[0016]** Subject of the present invention is also a kit of parts as claimed that comprises:

1. a) a preserved liquid aqueous pharmaceutical composition according to the present invention; and
2. b) a package leaflet including the information that the pharmaceutical composition is to be used for the prevention and/or treatment of a heart disease, preferably heart failure and/or hypertrophic cardiomyopathy, in a subject in need of such prevention or treatment.

**[0017]** It is completely unexpected that the pharmaceutical composition of the present invention as claimed can overcome the deficiencies of prior art. The liquid aqueous pharmaceutical compositions for oral administration comprising sparingly or not water-soluble pharmaceutically active compounds, such as pimobendan, known from prior art are usually not suitable due to the low concentration of pharmaceutically active compound normally achieved.

**[0018]** A known pharmaceutically active compound is pimobendan (4,5-dihydro-6-[2-(4-methoxyphenyl)-1 H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone) disclosed in EP 0 008 391 and having the formula:



**[0019]** Pimobendan is a well-known compound for the treatment of congestive heart failure (CHF) originating for example from dilated cardiomyopathy (DCM) or decompensated endocardiosis (DCE) in animals, especially dogs (WO 2005/092343). Furthermore, pimobendan is also used for the treatment of hypertrophic cardiomyopathy in cats (WO 2010/060874). Pimobendan is also approved as a drug product for cardiovascular treatment of humans.

**[0020]** As already described in EP 0 439 030 and WO 2005/08467, pimobendan drug substance is insoluble in water: 1 g drug substance is soluble in more than 10,000 mL. At pH 7 the solubility of pimobendan is only about 0.1 mg per 100 mL.

**[0021]** The solubility of pimobendan in aqueous solutions is depends on the pH. The solubility of pimobendan is significantly higher at pH 1 to 2.5 than at higher pH values (pH  $\geq$  3.0). However, the local tolerance and palatability as well as the chemical stability of such a formulation are not acceptable. This is due to the fact that the target dose would require a drug

concentration in solution which can only be achieved by a pH of about pH 2.5 and lower. However, the concentration has to be significantly higher, resulting in a low volume that the animal will have to swallow, than is possible at  $\text{pH} \geq 3.0$  in simple aqueous solutions. Accordingly, a pimobendan formulation comprising up to 1.5 mg/mL of pimobendan would need an increase in solubility at pH 7 by a factor of about 1000 to 1500, not achieved in prior art formulations for oral administration up to now.

**[0022]** On the contrary, the preserved liquid aqueous pharmaceutical compositions according to the present invention comprising at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble with the assistance of one or more etherified cyclodextrin derivatives as claimed provides an acceptable solubility of the pharmaceutically active compound such as pimobendan in aqueous solution. Thereby, an acceptable concentration of the pharmaceutically active compound is present allowing for use in an oral administration form.

**[0023]** Further, the one or more water-soluble preservatives present assure an acceptable efficacy of microbial preservation over the required shelf life of the pharmaceutical composition of the present invention.

**[0024]** Furthermore, and absolutely unexpected, the above water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivative(s), i.e. the included water-soluble preservatives do have a substantial preserving efficacy in the presence of cyclodextrin components.

**[0025]** Since the preserved liquid aqueous pharmaceutical compositions according to the present invention may be formulated for oral administration the disadvantageous side effects of parenteral administration such as inflammation in the subcutis following injections may be avoided. In addition, the composition does not have to be given by a veterinarian, as is the case for parenteral administration.

**[0026]** Also the palatability if administered to animal patients is found to be good apparently due to a high concentration of well-palatable etherified cyclodextrin-derivatives present in the pharmaceutical composition of the present invention.

**[0027]** Moreover, the addition of some excipients such as water-soluble polymers and/or antioxidants have been found to be advantageous in order to further increase the concentration of the pharmaceutically active compound to be used and/or to further stabilize the liquid pharmaceutical composition without interfering with the preservative effectiveness of the water-soluble preservatives.

## **DETAILED DESCRIPTION OF THE INVENTION**

**[0028]** Before the embodiments of the present invention are described in further details it shall



be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise.

**[0029]** Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. All given ranges and values may vary by 1 to 5 % unless indicated otherwise or known otherwise by the person skilled in the art, therefore, the term "about" was usually omitted from the description and claims. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the substances, excipients, carriers, and methodologies as reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

**[0030]** The present invention is based on the surprising unexpected observation that a pharmaceutical composition comprising one or more etherified cyclodextrin derivatives as claimed and at least one pharmaceutically active compound can be preserved, without occurrence of the above described deficiencies, in particular that included water-soluble preservatives as claimed do have a substantial preserving efficacy in the presence of cyclodextrin components.

**[0031]** According to the present invention a preserved liquid aqueous pharmaceutical composition as claimed is provided. The term "aqueous" is to be understood in the meaning that the pharmaceutical composition contains water as a solvent, whereby also one or more additional solvents may be optionally present. According to one preferred embodiments water is the only solvent of such pharmaceutically composition.

**[0032]** The liquid aqueous pharmaceutical composition comprises at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. According to the European Pharmacopoeia the solubility of a compound in water in the range of 15 to 25°C is defined as follows:

	Solvent in mL per gram compound
Very readily soluble	< 1
Readily soluble	from 1 to 10
Soluble	from > 10 to 30
Hardly soluble	from >30 to 100
Poorly soluble	from > 100 to 1,000
Very poorly soluble	from >1,000 to 10,000
Water-insoluble	> 10,000.



**[0033]** Thus, according to the present invention the at least one pharmaceutically active compound is poorly water-soluble, very poorly water-soluble or water-insoluble. Preferably the at least one pharmaceutically active compound is poorly water-soluble if more than 100 mL of water per gram compound have to be used; it is very poorly water-soluble if more than 1,000 mL of water per gram compound must be used; and it is water-insoluble if more than 10,000 mL water per gram compound have to be used to solubilise the compound.

**[0034]** The at least one pharmaceutically active compound is preferably a benzimidazole derivative. The benzimidazole derivative is preferably a substituted benzimidazole. The term "substituted benzimidazole" as used herein means, but is not limited to thiabendazol, fuberidazol, oxibendazol, parabendazol, cambendazol, mebendazol, fenbendazol, flubendazol, albendazol, oxfendazol, nocodazol, astemisol and pimobendan, pharmaceutically acceptable salts, derivatives, metabolites or prodrugs thereof. Most preferably, the term benzimidazole derivative as used herein means pimobendan, or any pharmaceutically acceptable salts thereof.

**[0035]** In another aspect the at least one pharmaceutically active compound is preferably an oxicam derivative. The oxicam derivative is preferably a substituted oxicam. The term "substituted oxicam" as used herein means, but is not limited to ampiroxicam, droxicam, lornoxicam, piroxicam, tenoxicam and meloxicam, pharmaceutically acceptable salts, derivatives, metabolites or prodrugs thereof. Most preferably, the term oxicam derivative as used herein means meloxicam, or any pharmaceutically acceptable salts thereof.

**[0036]** In another aspect the at least one pharmaceutically active compound is preferably an imidazolinone derivative. The imidazolinone derivative is preferably a substituted imidazolinone. The term "substituted imidazolinone" as used herein means, but is not limited to 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin), pharmaceutically acceptable salts, derivatives, metabolites or prodrugs thereof. Most preferably, the term imidazolinone derivative as used herein means 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin), or any pharmaceutically acceptable salts thereof.

**[0037]** In another aspect the at least one pharmaceutically active compound is preferably a glucopyranosyl-substituted benzene derivative. The glucopyranosyl-substituted benzene derivative is preferably a substituted glucopyranosyl-substituted benzene derivative. The term "substituted glucopyranosyl-substituted benzene derivative" as used herein means, but is not limited to 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, pharmaceutically acceptable salts, derivatives, metabolites or prodrugs thereof. Most preferably, the term glucopyranosyl-substituted benzene derivative as used herein means 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is

proline, more preferably L-proline.


**[0038]** The liquid aqueous pharmaceutical composition according to the present invention contains the at least one pharmaceutically active compound as disclosed herein, particularly in form of a substituted benzimidazole, more particularly pimobendan, preferably in the range of from 0.01 g/100 mL to 1 g/100 mL, more preferably from 0.05 g/100 mL to 0.5 g/100 mL, most preferably from 0.1 g/100 mL to 0.25 g/100 mL.

**[0039]** Due to the low aqueous solubility of the pharmaceutically active compound as disclosed herein, preferably a substituted benzimidazole, such as pimobendan, at pH values that are acceptable for an oral pharmaceutical composition, one or more solubilizing excipients need to be added to the formulation.

**[0040]** In the present invention such solubilizing excipients are one or more etherified cyclodextrin derivatives as claimed.

**[0041]** The liquid aqueous pharmaceutical composition according to the present invention contains the one or more etherified cyclodextrin derivatives as claimed preferably in the range of from 5 g/100 mL to 40 g/100 mL more preferably from 10 g/100 mL to 35 g/100 mL, most preferably from 20 g/100 mL to 35 g/100 mL per one etherified cyclodextrin derivative.

**[0042]** The term "etherified cyclodextrin derivative" as used herein refers to *i* etherified  $\beta$ -cyclodextrins of the chemical formula I:



(I),

in which the residues R are independently from each other hydroxyalkyl groups and part of the residues R may optionally independently from each other be alkyl groups. A partially etherified  $\beta$ -cyclodextrin of formula I is preferably used, in which the residues R are independently from each other hydroxyethyl, hydroxypropyl or dihydroxypropyl groups. Optionally, part of the residues R may for instance be methyl or ethyl groups.

**[0043]** The use of partially methylated  $\beta$ -cyclodextrins with 7 to 14 methyl groups in the  $\beta$ -cyclodextrin molecule as they are known from DE 31 18 218 does not fall under the present invention.

**[0044]** Partial ethers of  $\beta$ -cyclodextrin comprising only alkyl groups, such as methyl, ethyl and the like, may be particularly suitable in accordance with the invention if they have a low degree of substitution, preferably as defined below of 0.05 to 0.2.



**[0045]** Even more preferably, the one or more etherified cyclodextrin derivatives as used herein are hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, sulfobutyl-ether- $\beta$ -cyclodextrin.

**[0046]** Most preferably, the one or more etherified cyclodextrin derivatives as used herein are hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD), referred to as hydroxypropylbetadex in the European Pharmacopoeia. Hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD) of pharmaceutical grade is marketed for example under the Trademark Cavasol® W7 HP Pharma and can be ordered from Wacker, Germany.

**[0047]** Beta-cyclodextrin is a compound with ring structure consisting of 7 anhydro glucose units; it is also referred to as cycloheptaamylose. Each of the 7 glucose rings contains in 2-, 3-, and 6-position three hydroxy groups which may be etherified. In the partially etherified one or more  $\beta$ -cyclodextrin derivatives used according to the invention only part of these hydroxy groups is etherified with hydroxyalkyl groups and optionally further with alkyl groups. When etherifying with hydroxyalkyl groups, which can be carried out by reaction with the corresponding alkylene oxides, the degree of substitution is stated as molar substitution (MS), viz. in mole alkylene oxide per anhydroglucose unit (compare U.S. Patent 3,459,731, column 4). In the hydroxyalkyl ethers of  $\beta$ -cyclodextrin used in accordance with the invention the molar substitution is preferably between 0.05 and 10, more preferably between 0.2 and 2. Particularly preferred is a molar substitution of about 0.40 to about 1.50. The etherification with alkyl groups may be stated directly as degree of substitution (DS) per glucose unit which as stated above is 3 for complete substitution. Partially etherified  $\beta$ -cyclodextrins are used within the invention which preferably comprise besides hydroxyalkyl groups also alkyl groups, especially methyl or ethyl groups, up to a degree of substitution of 0.05 to 2.0, more preferably 0.2 to 1.5. Most preferably the degree of substitution with alkyl groups is between about 0.5 and about 1.2.

**[0048]** As solubilizing excipient hydroxypropyl- $\beta$ -cyclodextrin (HPBCD) showed very advantageous effects and resulted in the largest increase in solubility of a pharmaceutically active compound to be used such as pimobendan or a pharmaceutically acceptable salt thereof.

**[0049]** To prevent microbial growth in the solution during the in-use period one or more water-soluble preservatives are added to the liquid aqueous pharmaceutical composition. Therefore, the liquid aqueous pharmaceutical composition of the present invention comprises one or more water-soluble preservatives as claimed. The one or more water-soluble preservatives are selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof. | Particularly preferred is sorbic acid or salts thereof.

**[0050]** The liquid aqueous pharmaceutical composition according to the present invention contains the one or more water-soluble preservatives preferably in the range of from 0.05



g/100 mL to 3.0 g/100 mL, more preferably from 0.10 g/100 mL to 1.0 g/100 mL, most preferably from 0.20 g/100 mL to 0.40 g/100 mL.

**[0051]** The above disclosed water-soluble preservatives do not displace the pharmaceutically active compound from the cyclodextrin complex. Furthermore and absolutely unexpected, the above water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivative.

**[0052]** Therefore, the water-soluble preservatives as listed above allow the provision of a preserved cyclodextrin-containing pharmaceutical composition which is particularly suitable for oral and/or parenteral use in veterinary medicine, preferably oral use.

**[0053]** Thus, according to one aspect, the present invention relates to a preserved liquid aqueous pharmaceutical composition as claimed comprising one or more etherified cyclodextrin derivatives, one or more water-soluble preservatives and at least one pharmaceutically active compound as disclosed herein, particularly in form of a substituted benzimidazole, more particularly pimobendan, wherein the one or more etherified cyclodextrin derivative is selected from the group consisting of: alpha-, beta-, and/or gamma-cyclodextrin ether.

**[0054]** According to a further aspect, the present invention relates to a preserved liquid aqueous pharmaceutical composition as described above and as claimed, comprising one or more etherified cyclodextrin derivatives, one or more water-soluble preservatives and at least one pharmaceutically active compound as disclosed herein, particularly in form of a substituted benzimidazole, more particularly pimobendan, wherein the one or more etherified cyclodextrin derivative is etherified  $\beta$ -cyclodextrin. Preferably, that etherified  $\beta$ -cyclodextrin is hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, or dihydroxypropyl- $\beta$ -cyclodextrin. Even more preferably, that etherified  $\beta$ -cyclodextrin is hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD), referred to as hydroxypropylbetadex in the European Pharmacopoeia.

**[0055]** The preserved liquid aqueous pharmaceutical composition according to the present invention may contain one or more excipients. The one or more excipients can be selected from the group consisting of an antioxidant, a water-soluble polymer, buffer, pH adjustment agent, colorants or taste-masking ingredients including flavours.

**[0056]** Preferably at least one water-soluble antioxidant and/or at least one water-soluble polymer may be used. More preferably, at least one water-soluble antioxidant and at least one water-soluble polymer are added as excipients.

**[0057]** In a preferred embodiment, the liquid aqueous pharmaceutical composition of the present invention further comprises at least one water-soluble antioxidant and/or at least one water-soluble polymer, more preferably at least one water-soluble antioxidant and at least one water-soluble polymer.

**[0058]** Thus, according to a preferred embodiment the present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising

- one or more etherified cyclodextrin derivatives as claimed,
- one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof;
- at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;  
with the proviso that corticosteroids, in particular prednisolone and its prodrug prednisolone acetate (see US 2004/152664), and fluoroquinolones, in particular ciprofloxacin, gatifloxacin, moxifloxacin, sitafloxacin, lomefloxacin, grepafloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin, trovafloxacin and the like (see WO 2004/089418), are independently from each other excluded as pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble; and
- at least one water-soluble antioxidant.

**[0059]** According to the invention it is preferred that the liquid aqueous pharmaceutical composition comprises at least one water-soluble antioxidant because a combination of a water-soluble preservative and an antioxidant in order to stabilize the water-soluble preservative is particularly preferred. Only a small number of antioxidants are known which are water-soluble and come into question, such as free-radical scavengers, reduction agents and/or chelating agents. Water-soluble antioxidants that can be used comprise ascorbic acid or pharmaceutically acceptable salts thereof, particularly sodium ascorbate; citric acid (anhydrous and/or monohydrate) or pharmaceutically acceptable salts thereof, particularly sodium citrate; erythorbic acid; fumaric acid; malic acid; monothioglycerol; phosphoric acid; sodium metabisulfite; potassium metabisulfite; propionic acid; sodium bisulfite; sodium sulfite; resveratrol, butylhydroxyanisol, gallate derivatives, particularly propylgallate, or combinations thereof, preferably ascorbic acid or pharmaceutically acceptable salts thereof, citric acid (anhydrous and/or monohydrate) or pharmaceutically acceptable salts thereof, sodium metabisulfite, or potassium metabisulfite. Particularly preferred is ascorbic acid or pharmaceutically acceptable salts thereof.

**[0060]** A preservative system comprising one or more water-soluble preservatives preferably in form of an acid or salt thereof and at least one water-soluble antioxidant has been shown to be particularly efficient in preserving the above described liquid aqueous pharmaceutical compositions without having a negative effect on the concentration of the pharmaceutically active compound in the pharmaceutical compositions. Accordingly, in a preferred embodiment, the liquid aqueous pharmaceutical composition of the invention comprises one or more water-soluble preservatives as claimed and at least one water-soluble antioxidant.



**[0061]** It was found that in particular sorbic acid or a salt thereof shows advantageous characteristics and preserves the liquid aqueous pharmaceutical composition adequately, albeit at a higher concentration than in solutions not containing a cyclodextrin. From the viewpoint of antimicrobial preservation the pH range of 2.5 to 4.5, in particular 3.5, is advantageous of (1) being in the acidic range (improved antimicrobial activity even without a preservative) and (2) being well below the acid dissociation constant ( $pK_a$ ) value of 4.75 for sorbic acid. Only at pH values below  $pK_a$  most of the sorbic acid is present in the protonated (uncharged) state, which is necessary for diffusion through the cell membrane of bacteria and fungi.

**[0062]** Furthermore, the presence of at least one water-soluble antioxidant has a positive influence on the pharmaceutical composition of the present invention:

The water-soluble antioxidant, preferably ascorbic acid or salts thereof, was found to chemically stabilize the one or more water-soluble preservatives, for example sorbic acid or salts thereof, in the formulation.

**[0063]** Furthermore, the solubility of the one or more water-soluble preservatives could be increased if at least one antioxidant was present. Tests showed an increase in solubility of sorbic acid by about 0.25% (m/V) by the addition of ascorbic acid.

**[0064]** Furthermore, some water-soluble preservatives such as sorbic acid and potassium sorbate are sensitive to oxidation so that at least one antioxidant should preferably be added.

**[0065]** Small amounts of antioxidant may have a benefit for the pharmaceutical composition according to the present invention.

**[0066]** In a further aspect the liquid aqueous pharmaceutical composition according to the present invention comprises at least one water-soluble antioxidant preferably in the range of from 0.2 g/100 mL to 2.0 g/100 mL, in particular from 0.3 g/100 mL to 1.0 g/100 mL.

**[0067]** In a further aspect the liquid aqueous pharmaceutical composition according to the present invention comprises a ratio of water-soluble preservative and antioxidant preferably being from 0.1 to 10, in particular from 0.1 to 1.5, most preferably from 0.2 to 0.8.

**[0068]** According to the invention it has been found that the concentration of the pharmaceutically active compound that is dissolved with the assistance of one or more etherified cyclodextrin derivatives as claimed may be further increased by the addition of at least one water-soluble polymer.

**[0069]** It has been found that the water-soluble polymer does not influence the preservative effectiveness. Furthermore, the described formation of self-assembled complexes and/or formation of aggregates may be further reduced or completely prevented by excipients that solubilise and stabilize such aggregates, e.g. water-soluble polymers such as cellulose derivatives.



**[0070]** In addition, inclusion of such water-soluble polymers in the formulation can be used to optimize the viscosity of the oral solution to ease dosing for example from a plastic syringe.

**[0071]** According to the invention the at least one water-soluble polymer has preferably a molar mass of 5,000 to 500,000 g/mol, more preferably 10,000 to 300,000 g/mol, even more preferred 15,000 to 200,000 g/mol, even more preferred 20,000 to 200,000 g/mol. Examples for said water soluble polymer are hydroxypropyl methylcellulose (hypromellose, HPMC), hydroxypropyl cellulose, carboxymethylcellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, ethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylacetate as well as combinations or copolymers thereof, preferably hydroxypropyl methylcellulose (hypromellose).

**[0072]** The liquid aqueous pharmaceutical composition according to the present invention optionally contains the at least one water-soluble polymer preferably in the range of from 0.01 g/100 mL to 0.75 g/100 mL, more preferably from 0.02 g/100 mL to 0.50 g/100 mL, most preferably from 0.05 g/100 mL to 0.30 g/100 mL.

**[0073]** Thus, according to a preferred embodiment the present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising

- one or more etherified cyclodextrin derivatives as claimed;
- one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof;
- at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;  
with the proviso that corticosteroids, in particular prednisolone and its prodrug prednisolone acetate (see US 2004/152664), and fluoroquinolones, in particular ciprofloxacin, gatifloxacin, moxifloxacin, sitafloxacin, lomefloxacin, grepafloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin, trovafloxacin and the like (see WO 2004/089418), are independently from each other excluded as pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble; and
- at least one water-soluble polymer.

**[0074]** According to the invention the pH of the pharmaceutical composition for oral use has a pH value 2.5 to 5, most preferably 3 to 5. Particularly preferred is pH 3.4 to 5, especially 3.4 to 4. By using the lowest preferred, but still acceptable pH value, it is possible to further increase the solubility of the pharmaceutically active compound as disclosed herein, such as pimobendan, compared to that at higher pH values. Besides the better solubility of the pharmaceutically active compound compared to higher pH values, the lower pH value range has the further advantage of improved preservative efficacy. An improved preservative efficacy

results in a lower concentration of a given preservative which is required to achieve an adequate preservative effect.

**[0075]** According to a further preferred embodiment the present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising

- one or more etherified cyclodextrin derivatives as claimed;
- one or more water-soluble preservatives ; selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof,
- at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;  
with the proviso that corticosteroids, in particular prednisolone and its prodrug prednisolone acetate (see US 2004/152664), and fluoroquinolones, in particular ciprofloxacin, gatifloxacin, moxifloxacin, sitafloxacin, lomefloxacin, grepafloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin, trovafloxacin and the like (see WO 2004/089418), are independently from each other excluded as pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble;
- at least one water-soluble antioxidant; and
- at least one water-soluble polymer.

**[0076]** According to a further aspect, the present invention relates to a liquid aqueous pharmaceutical composition as described above and claimed, comprising at least one pharmaceutically active compound in the form of at least one substituted benzimidazole or a pharmaceutically acceptable salt thereof or a substituted oxicam or a pharmaceutically acceptable salt thereof or a substituted imidazolinone or a pharmaceutically acceptable salt thereof or a substituted glucopyranosyl-substituted benzene derivative or a pharmaceutically acceptable form and/or salt thereof, one or more etherified cyclodextrin derivatives in the form of etherified  $\beta$ -cyclodextrin as claimed, one or more water-soluble preservatives as claimed, optionally at least one water-soluble polymer and optionally at least one water-soluble antioxidant.

**[0077]** Therefore, the present invention preferably relates to a liquid aqueous pharmaceutical composition as described above and claimed, comprising

1. a) at least one pharmaceutically active compound in the form of a substituted benzimidazole or a pharmaceutically acceptable salt thereof, preferably thiabendazol, fuberidazol, oxibendazol, parabendazol, cambendazol, mebendazol, fenbendazol, flubendazol, albendazol, oxfendazol, nocodazol, astemisol or pimobendan, or pharmaceutical acceptable salts thereof, more preferably pimobendan or a pharmaceutically acceptable salt thereof;
2. b) one or more etherified cyclodextrin derivatives in the form of etherified  $\beta$ -cyclodextrin,



- preferably hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, more preferably hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD);
3. c) one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, benzoic acid or salts thereof, benzalkonium chloride, or combinations thereof, more preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof, most preferably sorbic acid or salts thereof;
  4. d) optionally, but according to a preferred embodiment, at least one water-soluble antioxidant, preferably ascorbic acid or a salt thereof; citric acid (anhydrous and/or monohydrate) or a salt thereof; sodium metabisulfite, potassium metabisulfite or resveratrol; and
  5. e) optionally, but according to a preferred embodiment, at least one water-soluble polymer with a molar mass of 5,000 to 500,000 g/mol, preferably 10,000 to 300,000 g/mol, even more preferred 15,000 to 200,000 g/mol, even more preferred 20,000 to 200,000 g/mol, preferably hydroxypropyl methylcellulose, hydroxypropyl cellulose, or methylcellulose, more preferably hydroxypropyl methylcellulose (hypromellose).

**[0078]** Therefore, the present invention preferably relates to a liquid aqueous pharmaceutical composition as described above and claimed, comprising

1. a) at least one pharmaceutically active compound in the form of a substituted oxicam or a pharmaceutically acceptable salt thereof, preferably ampiroxicam, droxicam, lornoxicam, piroxicam, tenoxicam and meloxicam, or pharmaceutical acceptable salts thereof, more preferably meloxicam or a pharmaceutically acceptable salt thereof;
2. b) one or more etherified cyclodextrin derivatives in the form of etherified  $\beta$ -cyclodextrin, preferably hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, more preferably hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD);
3. c) one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, benzoic acid or salts thereof, benzalkonium chloride; or combinations thereof, more preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof, most preferably sorbic acid or salts thereof;
4. d) optionally, but according to a preferred embodiment, at least one water-soluble antioxidant, preferably ascorbic acid or a salt thereof; citric acid (anhydrous and/or monohydrate) or a salt thereof; sodium metabisulfite, potassium metabisulfite or resveratrol; and
5. e) optionally, but according to a preferred embodiment, at least one water-soluble polymer with a molar mass of 5,000 to 500,000 g/mol, preferably 10,000 to 300,000 g/mol, even more preferred 15,000 to 200,000 g/mol, even more preferred 20,000 to 200,000 g/mol, preferably hydroxypropyl methylcellulose, hydroxypropyl cellulose, or methylcellulose, more preferably hydroxypropyl methylcellulose (hypromellose).



**[0079]** Therefore, the present invention preferably relates to a liquid aqueous pharmaceutical composition as described above and claimed, comprising

1. a) at least one pharmaceutically active compound in the form of a substituted imidazolinone or a pharmaceutically acceptable salt thereof, preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a pharmaceutically acceptable salt thereof;
2. b) one or more etherified cyclodextrin derivatives in the form of etherified  $\beta$ -cyclodextrin, preferably hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, more preferably hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD);
3. c) one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, benzoic acid or salts thereof, benzalkonium chloride; or combinations thereof, more preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof, most preferably sorbic acid or salts thereof;
4. d) optionally, but according to a preferred embodiment, at least one water-soluble antioxidant, preferably ascorbic acid or a salt thereof; citric acid (anhydrous and/or monohydrate) or a salt thereof; sodium metabisulfite, potassium metabisulfite or resveratrol; and
5. e) optionally, but according to a preferred embodiment, at least one water-soluble polymer with a molar mass of 5,000 to 500,000 g/mol, preferably 10,000 to 300,000 g/mol, even more preferred 15,000 to 200,000 g/mol even more preferred 20,000 to 200,000 g/mol, preferably hydroxypropyl methylcellulose, hydroxypropyl cellulose, or methylcellulose, more preferably hydroxypropyl methylcellulose (hypromellose).

**[0080]** Therefore, the present invention preferably relates to a liquid aqueous pharmaceutical composition as described above and claimed, comprising

1. a) at least one pharmaceutically active compound in the form of a substituted glucopyranosyl-substituted benzene derivative or a pharmaceutically acceptable salt thereof, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or pharmaceutical acceptable salts thereof, more preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline;
2. b) one or more etherified cyclodextrin derivatives in the form of etherified  $\beta$ -cyclodextrin, preferably hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -

- cyclodextrin, more preferably hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD);
3. c) one or more water-soluble preservatives selected from the group consisting of sorbic acid or salts thereof, benzoic acid or salts thereof, benzalkonium chloride; or combinations thereof, more preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; or combinations thereof, most preferably sorbic acid or salts thereof;
  4. d) optionally, but according to a preferred embodiment, at least one water-soluble antioxidant, preferably ascorbic acid or a salt thereof; citric acid (anhydrous and/or monohydrate) or a salt thereof; sodium metabisulfite, potassium metabisulfite or resveratrol; and
  5. e) optionally, but according to a preferred embodiment, at least one water-soluble polymer with a molar mass of 5,000 to 500,000 g/mol, preferably 10,000 to 300,000 g/mol, even more preferred 15,000 to 200,000 g/mol, even more preferred 20,000 to 200,000 g/mol, preferably hydroxypropyl methylcellulose, hydroxypropyl cellulose, or methylcellulose, more preferably hydroxypropyl methylcellulose (hypromellose).

**[0081]** The liquid aqueous pharmaceutical composition according to the present invention preferably comprises:

1. a) 0.01 g/100 mL to 1 g/100 mL substituted benzimidazole or a pharmaceutically acceptable salt thereof, preferably pimobendan or a pharmaceutically acceptable salt thereof, or a substituted oxicam or a pharmaceutically acceptable salt thereof, preferably meloxicam or a pharmaceutically acceptable salt thereof, or a substituted imidazolinone or a pharmaceutically acceptable salt thereof, preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a pharmaceutically acceptable salt thereof, or a substituted glucopyranosyl-substituted benzene derivative or a pharmaceutically acceptable form and/or salt thereof, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline;
2. b) 5 g/100 mL to 40 g/100 mL of one or more etherified cyclodextrin-derivatives as claimed, preferably hydroxypropyl- $\beta$ -cyclodextrin;
3. c) 0.05 g/100 mL to 3.0 g/100 mL of at least one water-soluble preservative as claimed, preferably sorbic acid or a salt thereof;
4. d) optionally, but according to a preferred embodiment, 0.2 g/100 mL to 2.0 g/100 mL of at least one water-soluble antioxidant, preferably ascorbic acid or a salt thereof and
5. e) optionally, but according to a preferred embodiment, 0.01 g/100 mL to 0.75 g/100 mL of at least one water-soluble polymer, preferably hydroxypropyl methylcellulose (hypromellose).



**[0082]** According to another aspect the liquid aqueous pharmaceutical composition according to the present invention preferably comprises:

1. a) 0.1 g/100 mL to 0.25 g/100 mL pimobendan or a pharmaceutically acceptable salt thereof or meloxicam or a pharmaceutically acceptable salt thereof or 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoïn) or a pharmaceutically acceptable salt thereof or 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline;
2. b) 20 g/100 mL to 35 g/100 mL of a hydroxypropyl- $\beta$ -cyclodextrin;
3. c) 0.05 g/100 mL to 0.30 g/100 mL of hydroxypropyl methylcellulose (hypromellose);
4. d) 0.20 g/100 mL to 0.40 g/100 mL of a water-soluble preservative as claimed, preferably sorbic acid or a salt thereof;
5. e) 0.3 g/100 mL to 1.0 g/100 mL of an antioxidant, preferably ascorbic acid or a salt thereof;

wherein optionally the pH of the composition is between 2.5 to 5, even more preferably 3 to 5, even more preferably 3.4 to 5 and most preferably 3.4 to 4.

**[0083]** With regard to the palatability if administered to animal patients the liquid aqueous pharmaceutical composition is well accepted.

**[0084]** The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound as disclosed herein, such as pimobendan in aqueous solution, according to which a minimum concentration of the pharmaceutically active compound is present allowing for use in an oral administration form. For example, the minimum concentration of pimobendan is preferably 1.5 mg/mL = 0.15% (m/V). Furthermore, there is only a negligible crystal growth of the pharmaceutically active compound, if any, during the storage period. Further, the one or more water-soluble preservatives present assure the acceptable efficacy of microbial preservation. In addition, the chemical long-term stability of the active ingredient has been found to be good according to an accelerated stability test in the range of  $3.0 \leq \text{pH} \leq 6.0$ .

**[0085]** The person skilled in the art knows the effective dosage of pharmaceutically active compounds as disclosed herein, such as benzimidazole derivatives, in particular pimobendan, and is readily able to adjust this dosage which is to be administered to the patient such as an animal patient, in need thereof. In order to have a general guidance in this connection a general therapeutic effective target dose, in particular for the treatment of HCM in cats, is about 0.1 mg to 0.5 mg pimobendan twice daily per kg bodyweight of the animal, preferably about 0.3 mg pimobendan twice daily per kg bodyweight of the animal.

**[0086]** The liquid aqueous pharmaceutical composition according to the present invention is intended for oral and/or parenteral administration, particularly oral solutions may be provided.

**[0087]** According to a preferred embodiment of the present invention the liquid aqueous pharmaceutical composition comprises the pharmaceutically active compound in form of a substituted benzimidazole, preferably pimobendan, or a substituted oxicam, preferably meloxicam, or a substituted imidazolinone, preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a substituted glucopyranosyl-substituted benzene derivative, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline, in a therapeutically effective amount of up to 5 mg/mL, preferably of 1.5 to 4 mg/mL, even more preferably of 1.5 to 3 mg/mL.

**[0088]** According to a further aspect, the present invention also relates to a method of treatment and/or prevention of diseases, wherein cardiotonic, hypotensive, anti-inflammatory and anti-thrombotic substances have a therapeutic benefit, preferably directed to a subject suffering from heart diseases, particularly a hypertrophic cardiomyopathy, comprising the step of administering to such subject in need of such treatment a therapeutically effective amount of any of the liquid aqueous pharmaceutical compositions as described herein.

**[0089]** Preferably, the liquid aqueous pharmaceutical composition of the present invention is administered in a therapeutically effective amount from about 0.075 mg to about 0.5 mg in form of a substituted benzimidazole derivative, preferably pimobendan, or a substituted oxicam, preferably meloxicam, or a substituted imidazolinone preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a substituted glucopyranosyl-substituted benzene derivative, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline, per kg bodyweight of the animal, more preferably from about 0.2 mg to about 0.4 mg of the pharmaceutically active compound in form of a substituted benzimidazole derivative, preferably pimobendan, or a substituted oxicam, preferably meloxicam, or a substituted imidazolinone preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a substituted glucopyranosyl-substituted benzene derivative, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline, per kg bodyweight of the animal, even more preferably



about 0.3 mg of the pharmaceutically active compound in form of a substituted benzimidazole derivative, preferably pimobendan, or a substituted oxicam, preferably meloxicam, or a substituted imidazolinone preferably 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one (imepitoin) or a substituted glucopyranosyl-substituted benzene derivative, preferably 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene, or any pharmaceutically acceptable form and/or salt thereof, wherein the pharmaceutically acceptable form preferably is a crystalline complex between 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzene and one or more amino acids, preferably wherein the one or more amino acids is proline, more preferably L-proline, twice daily per kg bodyweight of the animal. Preferably, two doses are to be administered per day (twice daily administration).

**[0090]** The subject/patient in need of any such treatment mentioned above is a mammal, preferably a companion animal. The term "animal" as used herein includes but is not limited to companion animals such as dogs, cats, guinea pigs, hamsters, horses, cattle, goats, sheep or the like. Preferably, the subject in need of such treatment is a dog, horse or cat, most preferably a cat or dog.

**[0091]** The liquid aqueous pharmaceutical composition according to the present invention is for use in a method for treating a patient in need of such treatment, preferably selected from among the indications: heart failure (HF), congestive heart failure (CHF), acute CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), and heart failure due to HCM, RCM, DCM and/or UCM.

**[0092]** More preferably, the liquid aqueous pharmaceutical composition according to the present invention is for use in a method for treating a subject in need of such treatment, preferably an animal, in particular a companion animal, even more preferred horse, dog or cat, guinea pig, hamster, cattle, goat, sheep, in particular cat or dog, selected from among the indications: heart diseases, particularly a hypertrophic cardiomyopathy, more particularly heart failure (HF), congestive heart failure (CHF), acute CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), and heart failure due to HCM, RCM, DCM and/or UCM.

**[0093]** The present invention is also directed to the use of a liquid aqueous pharmaceutical composition as above defined for preparing a pharmaceutical composition for the treatment or prevention of diseases in a subject in need of such treatment, preferably selected from among the above indications.

**[0094]** In a preferred embodiment, the liquid aqueous pharmaceutical composition as defined above for use in the above mentioned methods is for oral and/or parenteral administration, preferably oral administration.

**[0095]** Also subject of the present invention is a kit of parts that comprises:

1. a) a preserved liquid aqueous pharmaceutical composition as described above; and
2. b) a package leaflet including the information that the pharmaceutical composition is to be used for the prevention and/or treatment of a heart disease, preferably heart failure and/or hypertrophic cardiomyopathy, in a subject in need of such prevention or treatment.

**[0096]** During the production it has been surprisingly found that it is preferable that the one or more water-soluble preservatives are added after the addition of the at least one pharmaceutically active compound as disclosed herein. In case the one or more water-soluble preservatives are added to the cyclodextrin mixture before the at least one pharmaceutically active compound, the solution may become turbid. If the one or more water-soluble preservatives are added after the at least one pharmaceutically active compound, the produced solution remains clear.

**[0097]** According to a further aspect, the present invention also relates to a manufacturing process for the production of any of the liquid aqueous pharmaceutical compositions as described herein. A process for producing the pharmaceutical composition comprises the steps of:

- adding at least one pharmaceutically active compound, one or more etherified cyclodextrin derivatives as claimed, one or more water-soluble preservatives as claimed, optionally one or more antioxidants and optionally at least one water-soluble polymer to water and mixing under stirring,
- adjusting the pH value using a pH adjustment agent,

wherein preferably the one or more water-soluble preservatives are added after the addition of the at least one pharmaceutically active compound.

**[0098]** In this regard it should be taken into account that the process of manufacturing may be arbitrarily selected from manufacturing processes of liquid pharmaceutical compositions known from prior art unless the one or more water-soluble preservatives are added after the addition of the at least one pharmaceutically active compound.

**[0099]** In the following a representative process is described which should not be construed to limit the present invention.

**[0100]** At first, water is weighed in. Optionally, the at least one water-soluble polymer is added, preferably in portions, to the water under stirring until the at least one water-soluble polymer is dissolved thereby obtaining a first liquid mixture (1a). Alternatively, the one or more etherified cyclodextrin derivatives are added to the water under stirring thereby obtaining a first liquid mixture (1b). Alternatively and optionally, the one or more etherified cyclodextrin derivatives are added to the first liquid mixture (1a) containing the at least one water-soluble polymer under stirring until the one or more etherified cyclodextrin derivatives are dissolved thereby



obtaining a first liquid mixture (1c). Then, an ultrasonic treatment of such first liquid mixture (1b) or (1c), preferably under stirring, may be optionally performed. The obtained first liquid mixture (1b) or (1c) is incubated at room temperature, preferably without stirring, for one or more minutes. Afterwards, the at least one pharmaceutically active compound is added, preferably in portions, under stirring until it is dissolved thereby obtaining a second liquid mixture (2). Subsequently, the one or more water-soluble preservatives are added, preferably in portions, to the obtained second liquid mixture (2) under stirring until they are dissolved thereby obtaining a third liquid mixture (3). Optionally, one or more antioxidants as well as further excipients, if so desired, are added, preferably in portions, to the third liquid mixture (3) during stirring thereby obtaining a fourth liquid mixture (4). Then, an ultrasonic treatment of the fourth liquid mixture (4), preferably under stirring, is optionally performed. The obtained fourth liquid mixture (4) is incubated at room temperature, preferably without stirring, for one or more minutes. Subsequently, the pH value of the obtained fourth liquid mixture (4) is determined and adjusted, if necessary, using a pH adjustment agent to the desired pH value thereby obtaining the liquid aqueous pharmaceutical composition of the present invention.

**[0101]** The at least one pharmaceutically active compound, one or more etherified cyclodextrin derivatives, one or more water-soluble preservatives, and one or more antioxidants and at least one water-soluble polymer are those as already described in detail supra. The pH adjustment agent is preferably hydrochloric acid and/or sodium hydroxide.

**[0102]** The amounts used depend from the at least one pharmaceutically active compound used as well as the intended treatment, administration route and the patient to be treated. The person skilled in the art is readily able to select and adjust the required amounts by his general knowledge.

**[0103]** The invention described will now be illustrated by figures. However, it is expressly pointed out that the figures are intended solely as an illustration and should not be regarded as restricting the invention.

#### **BRIEF DESCRIPTION OF THE FIGURES**

**[0104]** Further advantages, features, characteristics and aspects of the present invention arise from the drawings which show as follows

**Figure 1** a schematic diagram wherein the solubility of pimobendan is shown as a function of preservative, cyclodextrin type and pH value in solutions containing 25% (m/V) cyclodextrin;

**Figure 2** a schematic diagram wherein the solubility of pimobendan is shown as a function of type and concentration of polymer, salt or complexation agent; and

**Figure 3** a schematic diagram wherein the solubility of pimobendan is shown as a function of concentration of hydroxypropyl- $\beta$ -cyclodextrin and presence of sodium sorbate and hydroxypropyl methylcellulose (HPMC).

**[0105]** Figure 1 shows a schematic diagram wherein the solubility of pimobendan is indicated as a function of the water-soluble preservatives benzalkonium chloride, benzethonium chloride, cetalpyridinium chloride, sorbic acid, sodium sorbate, benzoic acid, and sodium benzoate, respectively. The last row of columns represents the reference control, which is the respective solution without preservative ("none").

**[0106]** Each water-soluble preservative has been used with pH values of 3.5, 4.5, 5.5, 7, and 9 in combination with a hydroxypropyl- $\beta$ -cyclodextrin abbreviated as " $\beta$ " and each water-soluble preservative has been used with pH values of 3.5, 4.5, 5.5, and 7 in combination with a hydroxypropyl- $\gamma$ -cyclodextrin abbreviated as " $\gamma$ ". The solutions contain 25% (m/V) cyclodextrin. Each column in the diagram shows the determined solubility of pimobendan as a function of preservative, cyclodextrin type and pH value.

**[0107]** In Figure 1 it can be seen that the highest solubility of pimobendan occurs at pH = 3.5. Furthermore, pimobendan is more soluble with hydroxypropyl- $\beta$ -cyclodextrin than hydroxypropyl- $\gamma$ -cyclodextrin. The highest pimobendan solubility is achieved with sodium sorbate for which the solubility is significantly higher compared with the results of the reference control wherein no preservative is present.

**[0108]** Figure 2 is a schematic diagram wherein the solubility of pimobendan is shown as a function of type and concentration of polymer, salt or complexation agent. In order to determine the degree of complexation, the effect of three different polymers, three different salts and one chelating agent on the solubility of pimobendan was tested.

**[0109]** The pH of the solution was 4.5. Metolose is hydroxypropyl methylcellulose = HPMC = Hypromellose. Klucel ELF is hydroxypropyl cellulose = HPC. The number after the chemical name indicates the concentration of additive in % (m/V).

**[0110]** The consistency of the reference values [e.g. "sodium sorbate" vs. "sodium sorbate (repeated)"] shows that the results are consistent between the different trials and serves as a plausibility check.

**[0111]** In Figure 2 it can be seen that the addition of HPMC results in a significant increase in the solubility of pimobendan. The addition of salts or disodium edetate does not significantly increase the solubility of pimobendan.

**[0112]** Figure 3 is a schematic diagram wherein the solubility of pimobendan is shown as a function of concentration of hydroxypropyl- $\beta$ -cyclodextrin and presence of sodium sorbate and hydroxypropyl methylcellulose (HPMC). Therefore, in Figure 3 the effect of sodium sorbate and HPMC on the solubility of pimobendan was illustrated, and also the effect of concentration of hydroxypropyl- $\beta$ -cyclodextrin on the pimobendan solubility. Concentrations of sodium sorbate



of 1.0% (m/V) and of HPMC of 0.1% (m/V) were used. The pH value was set to 4.5 using hydrochloric acid in all solutions.

[0113] In Figure 3 it can be seen that the results confirm that sodium sorbate significantly increases the solubility of pimobendan. Furthermore, the results also confirm that HPMC significantly increases the solubility of pimobendan. By use of both HPMC and sodium sorbate the solubility of pimobendan is significantly increased.

## EXAMPLES

### Example 1

#### Manufacturing process

[0114] In the following Table 1 exemplary pharmaceutical compositions according to the present invention are given in detail:

Table 1: Exemplary pharmaceutical compositions according to the present disclosure

Ingredient	Content [g/100 mL]	Function
Pimobendan	0.15 - 0.25	Pharmaceutically active compound
Hydroxypropyl- $\beta$ -cyclodextrin	15 - 35	Etherified cyclodextrin
Hydroxypropyl methylcellulose	0.05 - 2.5	Water-soluble polymer
Sorbic acid and/or	0.1 - 1.0	Water-soluble preservative
• potassium sorbate		
• sodium benzoate		
• sodium metabisulfite	0.05 - 1.0	Antioxidant
Ascorbic acid and/or		
• sodium ascorbate		
• sodium metabisulfite		
• citric acid		
• sodium citrate		
Hydrochloric acid 0.1 M	ad pH 3.1 - 4.0	pH adjustment
Water	ad 100 mL	Solvent

**[0115]** The production procedure of an exemplary pharmaceutical composition according to the present invention for a single small scale batch (100 mL) with a target pH value of 3.5 in form of a general instruction is as follows:

Weigh purified water. Add a magnetic stirrer.

Weigh hydroxypropyl methylcellulose (HPMC) and add in portions to the purified water under stirring.

Weigh hydroxypropyl- $\beta$ -cyclodextrin into a 100 mL glass bottle and add the HPMC solution under stirring until the hydroxypropyl- $\beta$ -cyclodextrin is dissolved.

Let incubate at room temperature without stirring for 10 minutes.

Weigh pimobendan and add in portions under stirring until pimobendan is dissolved.

Weigh sorbic acid and add in portions under stirring until sorbic acid is dissolved.

Weigh ascorbic acid and optionally free-radical scavengers (e.g. BHA or propyl gallate) and add in portions under stirring and nitrogen atmosphere until ascorbic acid and optionally free-radical scavengers are dissolved.

Let incubate at room temperature without stirring for 10 minutes.

Determine pH and, if necessary, adjust to 3.50.

## **Example 2**

### **Antimicrobial Efficacy**

**[0116]** The testing criteria applied are those for evaluation of antimicrobial activity for oral preparations according to Pharm. Eur. 7 (tests at 14 days and 28 days). The acceptance criteria of the Ph. Eur. 7, Method 5.1.3 "Efficacy of Antimicrobial Preservation" USP 34, and Method <51> Antimicrobial Effectiveness Testing are listed in the following Table 2.

Table 2 Criteria for evaluation of antimicrobial activity for oral preparations according to Pharm. Eur. 7 and USP 34

---



Type of micro-organism	Ph. Eur. 7 Method 5.1.3.		USP 34 Method <51>	
	Logarithmic reduction of microorganisms after			
	14 days	28 days	14 days	28 days
Bacteria	>3	No increase from 14 days <sup>1)</sup>	> 1.0	No increase from 14 days <sup>2)</sup>
Funghi	> 1	No increase from 14 days <sup>1)</sup>	No increase from initial calc. count <sup>2)</sup>	No increase from initial calc. count <sup>2)</sup>
<sup>1)</sup> for Ph. Eur: No increase = no increase in number <sup>2)</sup> for USP: No increase = not more than 0.5 log <sub>10</sub> units higher than reference value				

[0117] The formulations tested in the trial are shown in the following Table 3.

[0118] The following microorganisms were tested: Pseudomonas aeruginosa, Straphylococcus aureus, Escherichia coli, Candida albicans, Aspergillus brasiliensis, Zygosaccharomyces rouxi.

Formulation no.		6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
Concentration [g/100 mL]																	
0.15																	
25																	
0.1		0.6	0.7	0.8	0.2	0.2	0.4	0.4	-	-	-	-	-	-	-	-	
		-	-	-	0.2	-	0.4	-	-	-	-	-	-	-	-	-	
		-	-	-	0.2	-	-	0.4	-	-	-	-	-	-	-	-	
		-	-	-	-	-	-	-	0.2	0.4	0.6	0.8	1.0	0.8	-	-	
		-	-	-	-	-	-	-	-	-	-	-	-	-	0.1	0.1	
		0.05	0.05	0.05	0.05	0.05	0.05	0.05	-	-	-	-	-	0.05	-	0.05	
ad pH 3.5																	
ad 100 mL																	





Ingredient	Formulation No.								
	1	2	3	4	5	6	7	8	9
	Concentration [g/100 mL]								
Water, purified	ad 100 mL								

[0121] The following procedure was used to prepare the samples:

1. 1. Weigh entire amount of water into vessel
2. 2. Weigh entire amount of hydroxypropyl methylcellulose (HPMC) into a beaker and add slowly to stirred water. Stir until fully dissolved.
3. 3. Weigh entire amount of Hydroxypropyl-β-cyclodextrin (HPβCD) into a beaker and add slowly to stirred mixture. Stir until fully dissolved.
4. 4. Let solution stand at least 10 minutes
5. 5. Weigh entire amount of drug substance into a beaker and add slowly to stirred mixture. Stir until fully dissolved.
6. 6. Weigh entire amount of sorbic acid into a beaker and add slowly to stirred mixture. Stir until fully dissolved.
7. 7. Let solution stand at least 10 minutes
8. 8. Adjust pH to target value with HCl or NaOH
9. 9. Let solutions stand overnight and re-adjust pH to target value with HCl or NaOH

[0122] The solutions were found to have the following densities and appearances:

Table 5

Formulation/Solution	Density [g/mL]	Appearance
1	1.082	Clear, colorless, no particles
2	1.096	Clear, colorless, no particles
3	1.076	Clear, colorless, no particles
4	1.075	Clear, colorless, no particles
5	1.094	Clear, colorless, no particles
6	1.085	Clear, colorless, no particles
7	1.074	Clear, light yellow, no particles
8	1.080	Clear, colorless, no particles
9	1.082	Clear, colorless, no particles

Table 6

Microbial results for tested solutions: *E. coli* (bacterium), *P. aeruginosa* (bacterium) and *S. aureus* (bacterium)

Micro-organism	Colony forming units / g				
	Solution no.	Innoc.	7 days	14 days	28 days
	1	540 000	< 100	< 100	no data available

<i>Escherichia coli</i>	1	540 000	< 100	< 100	no data available
	2	540 000	7300	500	no data available
	3	540 000	< 100	< 100	no data available
	4	540 000	< 100	< 100	no data available
	5	540 000	48 000	2900	no data available
	6	540 000	< 100	< 100	no data available
	7	420 000	< 100	no data available	no data available
	8	Test not possible <sup>1)</sup>			
	9	Test not possible <sup>1)</sup>			
<i>Pseudomonas aeruginosa</i>	1	440 000	< 100	< 100	no data available
	2	440 000	< 100	< 100	no data available
	3	440 000	< 100	< 100	no data available
	4	440 000	< 100	< 100	no data available
	5	440 000	<sup>2)</sup>	16 000	no data available
	6	440 000	< 100	< 100	no data available
	7	500 000	< 100	no data available	no data available
	8	Test not possible <sup>1)</sup>			
	9	Test not possible <sup>1)</sup>			
<i>Staphylococcus aureus</i>	1	350 000	< 100	< 100	no data available
	2	350 000	< 100	< 100	no data available
	3	350 000	< 100	< 100	no data available
	4	350 000	< 100	< 100	no data available
	5	350 000	< 100	< 100	no data available
	6	350 000	< 100	< 100	no data available
	7	320 000	< 100	no data available	no data available
	8	Test not possible <sup>1)</sup>			
	9	Test not possible <sup>1)</sup>			

<sup>1)</sup> Test could not be started due to rapid microbial growth between filtration and start of test

<sup>2)</sup> Result not reliable due to high count

Table 7 Microbial results for tested solutions: *Z. rouxii* (yeast fungus), *C. albicans* (yeast fungus) and *A. brasiliensis* (mould fungus)

Micro-organism	Colony forming units / g				
	Solution no.	Innoc.	7 days	14 days	28 days
<i>Candida albicans</i>	1	380 000	< 100	< 100	no data available
	2	380 000	530 000	790 000	no data available
	3	380 000	< 100	< 100	no data available
	4	380 000	< 100	< 100	no data available
	5	380 000	500 000	660 000	no data available
	6	380 000	< 100	< 100	no data available
	7	370 000	< 100	no data available	no data available
	8	Test not possible <sup>1)</sup>			
	9	Test not possible <sup>1)</sup>			
<i>A. brasiliensis</i>	1	120 000	< 100	100	no data available
	2	120 000	290 000	190 000	no data available
	3	120 000	7800	< 100	no data available
	4	120 000	10 000	600	no data available
	5	120 000	830 000	740 000	no data available



Aspergill	6	120 000	3000	/00	no data available
	7	290 000	600	no data available	no data available
	8	Test not possible <sup>1)</sup>			
	9	Test not possible <sup>1)</sup>			

<sup>1)</sup> Test could not be started due to rapid microbial growth between filtration and start of test

[0123] It is seen from the results in Table 6 and 7 that a good antimicrobial efficacy is achieved through the use of sorbic acid as a water-soluble preservative. The solutions (no. 2 and 5) with no water-soluble preservative fail the criteria for evaluation of antimicrobial activity according to Ph. Eur. The solutions with methyl paraben and propyl paraben (no. 8 and 9) had such a high microbial growth that the test of antimicrobial efficacy was not possible.

#### Example 4:

[0124] Small amounts of antioxidant, for example ascorbic acid, surprisingly provided an improvement of the efficacy of microbial preservation:

Table 8 Formulation compositions in test of efficacy of microbial preservation:

Ingredient	Formulation no.			
	1	2	3	4
	Concentration [g/100 mL]			
Pimobendan	0,15	0,15	0,15	0,15
Hydroxypropyl- $\beta$ -cyclodextrin	25	25	25	25
Hydroxypropyl methylcellulose	0,1	0,1	0,1	0,1
Sorbic acid	0,3	0,3	0,3	0,3
Ascorbic acid	0.20	0.35	0.50	0.70
HCl q.s. ad	pH 3.5	pH 3.5	pH 3.5	pH 3.5
Water, purified	ad 100 mL			

Table 9 Microbiological results according to Pharm. Eur. Method 2.6.12. for the fungi *Zygosaccharomyces rouxii*, *Candida albicans* and *Aspergillus brasiliensis* with varying concentrations of ascorbic acid.

Micro-organism	Formulation no. / incubation period (days)							
	1		2		3		4	
	14d	28d	14d	28d	14d	28d	14d	28d
<i>Zygosaccharomyces rouxii</i>	a	a	a	a	a	a	a	a
<i>Candida albicans</i>	b	a	a	a	a	a	a	a
<i>Aspergillus brasiliensis</i>	c	c	c	b	b	b	b	a

Codes: a: <LOQ CFU /mL, b: LOQ - 1000 CFU/mL, c: > 1000 -10 000 CFU / mL,

where CFU = colony forming units and LOQ = limit of quantification

[0125] The above results demonstrate the increasing efficacy of preservation with increasing concentration of antioxidant, such as ascorbic acid.

**Example 5:**

[0126] The formulations according to EP 1 920 785, paragraph [0067] were produced (see table 10).

Table 10

Material	mg/10ml	
	Formulation # 1	Formulation # 2
Pirnobendan	10.0	7.5
Kispiose HP (HP $\beta$ CD)	3300,0	3000,0
Disodium hydrogen phosphate dedecahydrate	17.6	17.6
Sodium dihydrogen phosphate dihydrate	8.0	8.0
Methyl paraben	20.0	10.0
Propyl paraben	5.0	5.0
Disodium odetate	5.0	5.0
Water for injection	q.s. to 10 ml	q.s. to 10 ml

[0127] Both formulations were clear, colourless and showed no particles. Formulation #1 has a measured pH of 8.2. Formulation #2 has a measured pH of 7.6.

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description



- WO8502767A [0004] [0004]
- US2004152664A [0005] [0013] [0058] [0073] [0075]
- WO2004089418A [0006] [0013] [0058] [0073] [0075]
- EP1920785A [0007] [0126]
- EP0008391A [0018]
- WO2005092343A [0019]
- WO2010060874A [0019]
- EP0439030A [0020]
- WO200508467A [0020]
- DE3118218 [0043]
- US3459731A [0047]

**Non-patent literature cited in the description**


- **LOFTSSON T et al.**Journal of Pharmaceutical Sciences, 2012, vol. 101, 93019-3032 [0002]
- **BREWSTER ME et al.**Advanced Drug Delivery Reviews, 2007, vol. 59, 645-666 [0002]
- **MESSNER M et al.**International Journal of Pharmaceutics, 2011, vol. 408, 235-247 [0002]
- **LOFTSSON T et al.**Drug Development and Industrial Pharmacy, 1992, vol. 18, 131477-1484 [0003]
- **BREWSTER ME**Advanced Drug Delivery Reviews, 2007, vol. 59, 7645-666 [0007]
- **Sciences Techniques et Pratiques STP Pharma Pratiques**, 1999, vol. 9, 3257-260 [0009]
- **Efficacy of Antimicrobial Preservation**Ph. Eur. 7, Method 5.1.3, [0116]

## P A T E N T K R A V

1. Konserveret flydende vandig farmaceutisk sammensætning omfattende:

- én eller flere etherificerede cyclodextrinderivater, hvor det ene eller de flere etherificerede cyclodextrinderivater er etherificeret  $\beta$ -cyclodextrin som har den kemiske formel I

5



(I)

i hvilket resterne R uafhængigt af hinanden er hydroxyalkylgrupper og en del af resterne R kan eventuelt uafhængigt af hinanden være alkylgrupper.;

- én eller flere vandopløselige konserveringsmidler valgt fra gruppen bestående af sorbinsyre eller salte deraf, fortrinsvis natriumsorbat, kaliumsorbat, calciumsorbat; benzoesyre eller salte deraf, fortrinsvis natriumbenzoat; benzalkoniumchlorid; eller kombinationer deraf; og
- mindst én farmaceutisk aktiv forbindelse som er svært vandopløselig, meget svært vandopløselig eller vanduopløselig;

10

15

med det forbehold at prednisolon og sit pro-drug prednisolonacetat, og ciprofloxacin, gatifloxacin, moxifloxacin, sitafloxacin, lomexifloxacin, grepafloxacin, gemifloxacin, norfloxacin, ofloxacin, levofloxacin og trovafloxacin, uafhængigt af hinanden er ekskluderet som farmaceutisk aktiv forbindelse som er svært vandopløselig, meget svært vandopløselig eller vanduopløselig;

20

og hvor pH af sammensætningen er mellem 2,5 og 5.

25

2. Flydende farmaceutisk sammensætning ifølge krav 1, hvor den farmaceutiske sammensætning yderligere omfatter mindst én vandopløselig antioxidant, som fortrinsvis er valgt fra gruppen bestående af ascorbinsyre eller farmaceutisk acceptable salte deraf, især natriumascorbat; citronsyre (vandfrit og/eller monohydrat) eller farmaceutisk acceptable salte deraf, mere fortrinsvis natriumcitrat; erythorbinsyre; fumarsyre; æblesyre; monothioglycerol; phosphorsyre; natrium-metabisulfit; kalium-metabisulfit; propionsyre; natriumbisulfit; natriumsulfit; resveratrol; butylhydroxyanisol, gallatderivater, især propylgallat, eller kombinationer deraf, mest fortrinsvis ascorbinsyre eller farmaceutisk acceptable salte deraf, citronsyre (vandfrit og/eller monohydrat) eller farmaceutisk acceptable salte deraf, natrium-metabisulfit eller kalium-metabisulfit.

30

3. Flydende farmaceutisk sammensætning ifølge krav 1 eller 2, hvor den farmaceutiske sammensætning yderligere omfatter mindst én vandopløselig polymer, fortrinsvis



mindst én vandopløselig polymer og mindst én vandopløselig antioxidant.

4. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 3, hvor det ene eller de flere etherificerede cyclodextrinderivater er hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, sulphobutyl-  
5 ether- $\beta$ -cyclodextrin, fortrinsvis hydroxypropyl- $\beta$ -cyclodextrin.

5. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 3 til 4, hvor den mindst ene vandopløselige polymer er valgt blandt hydroxypropylmethylcellulose (hypromellose, HPMC), hydroxypropylcellulose, carboxymethylcellulose, hydroxyethylcellu-  
10 lyvinylacetat såvel som kombinationer eller copolymerer deraf, fortrinsvis hydroxypropyl-  
methylcellulose (hypromellose).

6. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 5, hvor den mindst ene farmaceutisk aktive forbindelse er valgt blandt:

- 15 (i) benzimidazolderivater, fortrinsvis substituerede benzimidazolderivater, mere fortrinsvis thiabendazol, fuberidazol, oxibendazol, parabendazol, cambendazol, mebendazol, fenbendazol, flubendazol, albendazol, oxfendazol, nocodazol, astemisol og pimobendan, farmaceutisk acceptable salte, derivater, metabolitter eller pro-drugs deraf, mest fortrinsvis pimobendan og farmaceutisk acceptable salte deraf; eller
- 20 (ii) oxicamderivater, fortrinsvis substituerede oxicamderivater, mere fortrinsvis ampiroxicam, droxicam, lornoxicam, piroxicam, tenoxicam og meloxicam, farmaceutisk acceptable salte, derivater, metabolitter eller pro-drugs deraf, mest fortrinsvis meloxicam og farmaceutisk acceptable salte deraf; eller
- 25 (iii) imidazolinonderivater, fortrinsvis substituerede imidazolinonderivater, mere fortrinsvis 1-(4-chlorphenyl)-4-(4-morpholiny)-2,5-dihydro-1H-imidazol-2-on (imepitoin), farmaceutisk acceptable salte, derivater, metabolitter eller pro-drugs deraf, mest fortrinsvis 1-(4-chlorphenyl)-4-(4-morpholiny)-2,5-dihydro-1H-imidazol-2-on (imepitoin) og farmaceutisk acceptable salte deraf; eller
- 30 (iv) glucopyranosyl-substituerede benzenderivater, fortrinsvis substituerede glucopyranosyl-substituerede benzenderivater, mere fortrinsvis 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen, eller en hvilken som helst farmaceutisk acceptabel form og/eller salt deraf, hvor den farmaceutiske acceptable form fortrinsvis er et krystallinsk kompleks mellem 1-cyano-2-  
35 (4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen og én eller flere aminosyrer, fortrinsvis hvor den ene eller de flere aminosyrer er prolin, mere fortrinsvis L-prolin.

7. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 6, hvor sammensætningen indeholder den ene eller de flere vandopløselige konserverings-

midler i området fra 0,05 g/100 mL til 3,0 g/100 mL, mere fortrinsvis fra 0,10 g/100 mL til 1,0 g/100 mL, mest fortrinsvis fra 0,20 g/100 mL til 0,40 g/100 mL.

8. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 2 til 7, hvor forholdet mellem vandopløseligt konserveringsmiddel og antioxidant er fra 0,1 til 10, især fra 0,1 til 1,5, mest fortrinsvis fra 0,2 til 0,8.

9. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 3 til 8, omfattende

- a) mindst én farmaceutisk aktiv forbindelse i formen af et substitueret benzimidazol eller et farmaceutisk acceptabelt salt deraf, fortrinsvis thiabendazol, fuberidazol, oxibendazol, parabendazol, cambendazol, mebendazol, fenbendazol, flubendazol, albendazol, oxfendazol, nocodazol, astemisol eller pimobendan, eller farmaceutisk acceptable salte deraf, mere fortrinsvis pimobendan, eller et farmaceutisk acceptabelt salt deraf; eller i formen af en substitueret oxicam eller et farmaceutisk acceptabelt salt deraf, fortrinsvis ampiroxicam, droxicam, lornoxicam, piroxicam, tenoxicam og meloxicam, eller farmaceutisk acceptable salte deraf, mere fortrinsvis meloxicam eller et farmaceutisk acceptabelt salt deraf; eller i formen af en substitueret imidazolinon eller et farmaceutisk acceptabelt salt deraf, fortrinsvis 1-(4-chlorphenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-on (imepitoïn) eller et farmaceutisk acceptabelt salt deraf; eller i formen af et glucopyranosyl-substitueret benzenderivat eller et farmaceutisk acceptabelt salt deraf, fortrinsvis 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen, eller en hvilken som helst farmaceutisk acceptabel form og/eller salt deraf, hvor den farmaceutisk acceptable form fortrinsvis er et krystallinsk kompleks mellem 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen og én eller flere aminosyrer, fortrinsvis hvor den ene eller de flere aminosyrer er prolin, mere fortrinsvis L-prolin;
- b) én eller flere etherificerede cyclodextrinderivater i formen af en etherificeret  $\beta$ -cyclodextrin, fortrinsvis hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, mere fortrinsvis hydroxypropyl- $\beta$ -cyclodextrin (HB $\beta$ CD);
- c) ét eller flere vandopløselige konserveringsmidler, fortrinsvis valgt fra gruppen bestående af sorbinsyre eller salte deraf, benzoesyre eller salte deraf, benzalkoniumchlorid, benzethoniumchlorid, cetylpyridiniumchlorid, natriummetabisulfit, natriumacetat; parabener og salte deraf, fortrinsvis methylparaben, ethylparaben, propylparaben, butylparaben, butylparabennatrium; eller kombinationer deraf, mere fortrinsvis valgt fra gruppen bestående af sorbinsyre eller salte deraf, benzoesyre eller salte deraf, benzalkoniumchlorid, benzethoniumchlorid, cetylpyridiniumchlorid, natriummetabisulfit, natriumace-



tat; eller kombinationer deraf, mest fortrinsvis sorbinsyre eller salte deraf;

d) eventuelt mindst én vandopløselig antioxidant, fortrinsvis ascorbinsyre eller et farmaceutisk acceptabelt salt deraf; citronsyre (vandfrit og/eller monohydrat) eller et farmaceutisk acceptabelt salt deraf; natrium-metabisulfit, kalium-metabisulfit eller resveratrol; og

e) eventuelt mindst én vandopløselig polymer med en molarmasse på 5.000 til 500.000 g/mol, fortrinsvis 10.000 til 300.000 g/mol, endnu mere fortrinsvis 15.000 til 200.000 g/mol, endnu mere fortrinsvis 20.000 til 200.000 g/mol, fortrinsvis hydroxypropylmethylcellulose, hydroxypropylcellulose eller methylcellulose, mere fortrinsvis hydroxypropylmethylcellulose (hypromellose).

10. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 3 til 9, hvor sammensætningen omfatter:

a) 0,1 g/100 mL til 0,25 g/100 mL pimobendan eller et farmaceutisk acceptabelt salt deraf; eller meloxicam eller et farmaceutisk acceptabelt salt deraf; eller 1-(4-chlorphenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-on (imepitoin) eller et farmaceutisk acceptabelt salt deraf; eller 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen, eller en hvilken som helst farmaceutisk acceptabel form og/eller salt deraf, hvor den farmaceutiske acceptable form fortrinsvis er et krystallinsk kompleks mellem 1-cyano-2-(4-cyclopropyl-benzyl)-4-( $\beta$ -D-glucopyranos-1-yl)-benzen og én eller flere aminosyrer, fortrinsvis hvor den ene eller de flere aminosyrer er prolin, mere fortrinsvis L-prolin;

b) 20 g/100 mL til 35 g/100 mL af et hydroxyethyl- $\beta$ -cyclodextrin;

c) 0,05 g/100 mL til 0,30 g/100 mL af hydroxypropylmethylcellulose (hypromellose);

d) 0,20 g/100 mL til 0,40 g/100 mL af et vandopløseligt konserveringsmiddel, fortrinsvis sorbinsyre eller et salt deraf;

e) 0,3 g/100 mL til 1,0 g/100 mL af en antioxidant, fortrinsvis ascorbinsyre eller et salt deraf.

11. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 10, hvor sammensætningen er til oral og/eller parenteral indgivelse, fortrinsvis oral indgivelse.

12. Flydende farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 11 til anvendelse i en fremgangsmåde til at behandle et individ som har behov for en sådan behandling, fortrinsvis et dyr, især et selskabsdyr, mere fortrinsvis hest, hund eller kat, marsvin, hamster, kvæg, ged, får, især kat eller hund, valgt blandt indikationerne: hjertesygdomme, især hypertrofisk kardiomyopati, mere især hjertesvigt (HF), kongestiv hjertesvigt (CHF), akut CHF, dekomenseret endokardiose (DCE), dilateret kardiomyopati (DCM), asymptomatisk (okkult) CHF, asymptomatisk DCM, hypertrofisk kardiomyopati

(HCM), restriktiv kardiomyopati (RCM) og hjertesvigt grundet HCM, RCM, DCM og/eller UCM.

13. Fremgangsmåde til at fremstille den farmaceutiske sammensætning ifølge et hvilket som helst af kravene 1 til 11, omfattende trinnene

- 5
- at tilføje mindst én farmaceutisk aktiv forbindelse, ét eller flere etherificerede cyclodextrinderivater, ét eller flere vandopløselige konserveringsmidler, eventuelt én eller flere antioxidanter og eventuelt mindst én vandopløselig polymer til vand og blande under omrøring,
  - at justere pH-værdien ved anvendelse af et pH-justeringsmiddel,
- 10 hvor fortrinsvis det ene eller de flere vandopløselige konserveringsmidler tilføjes efter tilføjelsen af den mindst ene farmaceutisk aktive forbindelse.

14. Kit i dele som omfatter:

- 15
- a) en konserveret flydende vandig farmaceutisk sammensætning ifølge et hvilket som helst af krav 1 til 11; og
  - b) en pakkefolder indbefattende informationen at den farmaceutiske sammensætning skal anvendes til forebyggelsen og/eller behandlingen af en hjertesygdom, fortrinsvis hjertesvigt og/eller hypertrofisk kardiomyopati, i et individ som har behov for sådan forebyggelse eller behandling.





Figure 2






Figure 3

